Not applicableUnknownNCT01697163What this trial is testingDe Novo Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase InhibitorsWho this might be right forNSCLC Severance Hospital 155
Testing effectiveness (Phase 2)Study completedNCT01250119What this trial is testingAssess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.Who this might be right forNon-Squamous Non-Small Cell Lung Cancer Hoffmann-La Roche 688
Large-scale testing (Phase 3)Study completedNCT02864251What this trial is testingNivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) TherapyWho this might be right forNon-Small-Cell Lung Carcinoma Bristol-Myers Squibb 367
Large-scale testing (Phase 3)UnknownNCT03727867What this trial is testingEfficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Early Stereotactic Body Radiation Therapy to the Primary Tumor in Advanced Non-small Cell Lung CancerWho this might be right forAdvanced Non-small Cell Lung Cancer Haihua Yang 300
Not applicableLooking for participantsNCT04151342What this trial is testingCAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)Who this might be right forCancerMalignancies MultipleMalignant Solid Tumor+7 more University Health Network, Toronto 5,500
Testing effectiveness (Phase 2)Study completedNCT04426825What this trial is testingAtezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung CancerWho this might be right forCarcinoma, Non-Small-Cell Lung Hoffmann-La Roche 23
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06319950What this trial is testingHigh-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain MetastasesWho this might be right forLung Cancer, Nonsmall Cell Taizhou Hospital 255
Early research (Phase 1)Ended earlyNCT02476955What this trial is testingOpen-label Phase 1b Study of ARQ 092 in Combination With AnastrozoleWho this might be right forSolid TumorsOvarian CancerEndometrial Cancer ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 41
Large-scale testing (Phase 3)Looking for participantsNCT06988475What this trial is testingDETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET DysregulationsWho this might be right forSolid TumourHaematological MalignancyMalignant Neoplasm+8 more Cancer Research UK 30
Early research (Phase 1)Active Not RecruitingNCT02503722What this trial is testingTesting the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung CancerWho this might be right forMetastatic Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell CarcinomaStage III Lung Non-Small Cell Cancer AJCC v7+3 more National Cancer Institute (NCI) 36
Large-scale testing (Phase 3)Study completedNCT02151981What this trial is testingAZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung CancerWho this might be right forAnticancer Treatment AstraZeneca 421
Testing effectiveness (Phase 2)Study completedNCT02442349What this trial is testingPhase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia PacificWho this might be right forNon-Small Cell Lung Cancer AstraZeneca 171
Testing effectiveness (Phase 2)UnknownNCT03502850What this trial is testingSafety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung CancerWho this might be right forLocally Advanced or Metastatic NSCLC Jiangsu Aosaikang Pharmaceutical Co., Ltd. 507
Testing effectiveness (Phase 2)UnknownNCT05326425What this trial is testingLazertinib in Patients With NSCLC With Asymptomatic or Mild Symptomatic Brain Metastases After Failure of EGFR TKI.Who this might be right forLung Neoplasms Jin Hyoung Kang 40
Testing effectiveness (Phase 2)Study completedNCT01833572What this trial is testingPreoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001)Who this might be right forNon-small-cell Lung Cancer Fudan University 36
Testing effectiveness (Phase 2)Study completedNCT06083662What this trial is testingNeratinib and Trastuzumab Biosimilar in Patients with HER2 Mutated Advanced Solid CancersWho this might be right forMetastatic CancerHER2 Gene Mutation Korea University Guro Hospital 42
Not applicableStudy completedNCT02777567What this trial is testingKOREA Study (Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy)Who this might be right forNon-Small Cell Lung Cancer AstraZeneca 315
Testing effectiveness (Phase 2)Ended earlyNCT02495233What this trial is testingASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)Who this might be right forNon-Small-Cell Lung Cancer Astellas Pharma Global Development, Inc. 10
Not applicableStudy completedNCT01167972What this trial is testingObservational Study on the Management of Patients With Non Small Cell Lung Cancer AdenocarcinomaWho this might be right forNon Small Cell Lung Cancer AstraZeneca 2,000
Not applicableStudy completedNCT03133234What this trial is testingEffect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLCWho this might be right forT790M Positive NSCLC Patients AstraZeneca 47